Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2026)
Dianthus Therapeutics' EBITDA Margin came in at -10166.92% for Q3 2025, down 8791.46 percentage points from -1375.46% a year earlier but up 7914.43 percentage points from the prior quarter.
Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2025, Dianthus Therapeutics reported EBITDA Margin of -4554.84%, down 3011.53 percentage points year-over-year; for FY2024, it was -1632.21%, up 70.09 percentage points from FY2023.
- Going back by year, EBITDA Margin was -1702.30% in FY2023 (-1485.56 pp) and -216.74% in FY2022.
- The five-year range for quarterly EBITDA Margin is -18081.35% (Q2 2025) to -135.01% (Q4 2022).
- Year-over-year, EBITDA Margin has declined for three consecutive quarters, with an average year-over-year change of -3790.38 percentage points over the last eight quarters.
- The fastest year-over-year change in EBITDA Margin over five years came in Q4 2024 (a gain of 425.66 percentage points), and the weakest in Q2 2025 (a drop of 16890.74 percentage points).
- Business Quant data shows DNTH's EBITDA Margin at -18081.35% (Q2 2025), -2850.39% (Q1 2025) and -2404.98% (Q4 2024) in the three quarters before Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Dianthus Therapeutics | 5.00 Bn | 4.95 Bn | - | -4,829.34% |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -4,829.34% |
| Jun 30, 2026 | -7,680.63% |
| Mar 31, 2026 | -9,300.20% |
| Dec 31, 2025 | -24,476.76% |
| Sep 30, 2025 | -10,166.92% |
| Jun 30, 2025 | -18,081.35% |
| Mar 31, 2025 | -2,850.39% |
| Dec 31, 2024 | -2,404.98% |
| Sep 30, 2024 | -1,375.46% |
| Jun 30, 2024 | -1,190.61% |
| Mar 31, 2024 | -2,039.13% |
| Dec 31, 2023 | -2,830.63% |
| Sep 30, 2023 | -1,703.46% |
| Jun 30, 2023 | -598.07% |
| Mar 31, 2023 | -744.06% |
| Dec 31, 2022 | -136.30% |
| Sep 30, 2022 | -656.86% |
Dianthus Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=DNTH&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "DNTH", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=DNTH&period=max&api_key=YOUR_API_KEY");
const data = await res.json();